Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Bailey

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry|November 11, 2008
C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitorsRoger Hunter, Yassir Younis, Clare I Muhanji, et al.
Journal of Medicinal Chemistry|October 9, 2007
From docking false-positive to active anti-HIV agentGabriela Barreiro, Joseph T Kim, Cristiano R W Guimarães, et al.
Leukemia|June 2, 2026
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitorsAditi Chatterjee, Moaath K Mustafa Ali, Christopher M Bailey, et al.
Biorxiv : the Preprint Server for Biology|December 4, 2025
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with <i>NRAS</i> mutations to FLT3 inhibitorsAditi Chatterjee, Moaath K Mustafa Ali, Christopher M Bailey, et al.
Journal of the American Chemical Society|July 1, 2008
Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculationsJacob G Zeevaart, Ligong Wang, Vinay V Thakur, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2007
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosineHirotomo Nakata, Masayuki Amano, Yasuhiro Koh, et al.
Cancer Research Communications|January 29, 2024
Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal DegradationJonelle K Lee, Aditi Chatterjee, Mario Scarpa, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2006
An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their disseminationToru Tobe, Scott A Beatson, Hisaaki Taniguchi, et al.
Molecular Cancer Therapeutics|February 11, 2021
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal DegradationMario Scarpa, Prerna Singh, Christopher M Bailey, et al.
Journal of Medicinal Chemistry|May 11, 2013
Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategyChristopher M Bailey, Todd J Sullivan, Pinar Iyidogan, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry|November 11, 2008
C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitorsRoger Hunter, Yassir Younis, Clare I Muhanji, et al.
Journal of Medicinal Chemistry|October 9, 2007
From docking false-positive to active anti-HIV agentGabriela Barreiro, Joseph T Kim, Cristiano R W Guimarães, et al.
Leukemia|June 2, 2026
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitorsAditi Chatterjee, Moaath K Mustafa Ali, Christopher M Bailey, et al.
Biorxiv : the Preprint Server for Biology|December 4, 2025
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with <i>NRAS</i> mutations to FLT3 inhibitorsAditi Chatterjee, Moaath K Mustafa Ali, Christopher M Bailey, et al.
Journal of the American Chemical Society|July 1, 2008
Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculationsJacob G Zeevaart, Ligong Wang, Vinay V Thakur, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2007
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosineHirotomo Nakata, Masayuki Amano, Yasuhiro Koh, et al.
Cancer Research Communications|January 29, 2024
Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal DegradationJonelle K Lee, Aditi Chatterjee, Mario Scarpa, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2006
An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their disseminationToru Tobe, Scott A Beatson, Hisaaki Taniguchi, et al.
Molecular Cancer Therapeutics|February 11, 2021
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal DegradationMario Scarpa, Prerna Singh, Christopher M Bailey, et al.
Journal of Medicinal Chemistry|May 11, 2013
Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategyChristopher M Bailey, Todd J Sullivan, Pinar Iyidogan, et al.
Pageof 5